



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

## Zosuquidar trihydrochloride (Standard)

<b>Cat. No.:</b>	HY-50671R
<b>CAS No.:</b>	167465-36-3
<b>Molecular Formula:</b>	C <sub>32</sub> H <sub>34</sub> Cl <sub>3</sub> F <sub>2</sub> N <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	636.99
<b>Target:</b>	P-glycoprotein
<b>Pathway:</b>	Membrane Transporter/Ion Channel
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Zosuquidar (trihydrochloride) (Standard) is the analytical standard of Zosuquidar (trihydrochloride). This product is intended for research and analytical applications. Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (K <sub>i</sub> =59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research <sup>[1][2][3]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Ki: 59nM (P-glycoprotein) <sup>[1]</sup> .

### REFERENCES

- [1]. A H Dantzig, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropylbenzimidazole modulator, LY335979. *Cancer Res.* 1996 Sep 15;56(18):4171-9.
- [2]. Ruoping Tang, et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). *BMC Cancer.* 2008 Feb 13;8:51.
- [3]. Larry D Cripe, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. *Blood.* 2010 Nov 18;116(20):4077-85.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA